These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24782258)

  • 1. Interferon-free strategies without a nucleoside/nucleotide analogue.
    Welzel TM; Zeuzem S
    Semin Liver Dis; 2014 Feb; 34(1):47-57. PubMed ID: 24782258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-free strategies with a nucleoside/nucleotide analogue.
    Feld JJ
    Semin Liver Dis; 2014 Feb; 34(1):37-46. PubMed ID: 24782257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.
    Welzel TM; Dultz G; Zeuzem S
    J Hepatol; 2014 Nov; 61(1 Suppl):S98-S107. PubMed ID: 25443350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic strategies in HCV: second-generation protease inhibitors.
    Clark VC; Peter JA; Nelson DR
    Liver Int; 2013 Feb; 33 Suppl 1():80-4. PubMed ID: 23286850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-combination strategies for the treatment of chronic hepatitis C.
    Aronsohn A; Jensen D
    Semin Liver Dis; 2014 Feb; 34(1):30-6. PubMed ID: 24782256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance mutations against HCV protease inhibitors and antiviral drug design.
    Shang L; Lin K; Yin Z
    Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting and host-targeting HCV inhibitors: current and future directions.
    Chatel-Chaix L; Germain MA; Götte M; Lamarre D
    Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targets for antiviral therapy of hepatitis C.
    Rupp D; Bartenschlager R
    Semin Liver Dis; 2014 Feb; 34(1):9-21. PubMed ID: 24782254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in Examination and Treatment of Hepatitis C Virus].
    Suda G; Sakamoto N
    Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.
    Franco S; Tural C; Nevot M; Moltó J; Rockstroh JK; Clotet B; Martinez MA
    Gastroenterology; 2014 Sep; 147(3):599-601.e1. PubMed ID: 24859204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New protease inhibitors for HCV--help is on the way.
    Fusco DN; Chung RT
    J Hepatol; 2011 Jun; 54(6):1087-9. PubMed ID: 21232563
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic strategies in HCV: polymerase inhibitors.
    Gerber L; Welzel TM; Zeuzem S
    Liver Int; 2013 Feb; 33 Suppl 1():85-92. PubMed ID: 23286851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.